Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

TG Therapeutics, Inc. - Common Stock (NQ:TGTX)

35.33 +0.35 (+1.00%)
Streaming Delayed Price Updated: 10:49 AM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TG Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
After Monday's panicked global sell-off, markets have calmed down. 
Via Investor's Business Daily
NASDAQ:TGTX is showing decent growth, but is still valued reasonably.
NASDAQ:TGTX stands out as a growth opportunity that won't break the bank. 
Via Chartmill
S&P 500 Surges Over 2%; Caterpillar Earnings Beat Estimates
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
Crude Oil Moves Higher; Yum! Brands Posts Upbeat Earnings
Via Benzinga
Exposures Fossil Fuels
$1000 Invested In TG Therapeutics 5 Years Ago Would Be Worth This Much Today
Via Benzinga
(TGTX) - Analyzing TG Therapeutics's Short Interest
Via Benzinga
Peering Into TG Therapeutics's Recent Short Interest
Via Benzinga
(TGTX) - Analyzing TG Therapeutics's Short Interest
Via Benzinga
TGTX Stock Earnings: TG Therapeutics Beats EPS, Beats Revenue for Q2 2024
TGTX stock results show that TG Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
TG Therapeutics Stock Jumps As Surprise Profit Smashes Views By 157%
The company unexpectedly reported profit in the second quarter, handily beating views for a per-share loss. 
Via Investor's Business Daily
In the world of growth stocks, NASDAQ:TGTX shines as a value proposition.
Looking for growth without the hefty price tag? Consider TG THERAPEUTICS INC (NASDAQ:TGTX). 
Via Chartmill
"Rule Breaker Investing" Market Cap Game Show: Bill Mann vs. Bill Barker
Our first-ever twin bill. 
Via The Motley Fool
Earnings Preview For TG Therapeutics
Via Benzinga
How Is The Market Feeling About TG Therapeutics?
Via Benzinga
Nasdaq 100 Overbought? Here’s What History Says About The Current Rally
Find out the historical patterns traders can look for to anticipate the next move in the Nasdaq 100. 
Via Talk Markets
The Most Shorted Stocks in June: Hold, Short, or Squeeze?
Given the proper catalyst, the short interest in these stocks may lead to a short squeeze. All the market needs is a push and it may come at any time. 
Via MarketBeat
Why TG Therapeutics Stock Was Rocketing Higher This Week
The company raised guidance for sales of its drug for relapsing multiple sclerosis. 
Via The Motley Fool
TGTX Stock Earnings: TG Therapeutics Misses EPS, Beats Revenue for Q1 2024
TGTX stock results show that TG Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
TG Therapeutics stock just rallied 30%: what happened?
TG Therapeutics Inc (NASDAQ: TGTX) is up 30% on Wednesday even though it reported a wider-than-expected per-share loss for its fiscal first quarter. 
Via Talk Markets
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
EQNX::TICKER_START (NASDAQ:TLSA),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:BIIB),(NASDAQ:TGTX) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Powell Industries Posts Upbeat Results, Joins A10 Networks, Garmin, DuPont And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
From FN Media Group LLC
Via GlobeNewswire
Why Is Multiple Sclerosis-Focused TG Therapeutics Stock Trading Higher Today?
TG Therapeutics exceeds expectations with Q4 2023 revenues of $43.97M. Briumvi's success in the U.S., Europe launch, and new patents drive optimism. TGTX shares surge 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Why AMD Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
TG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares?
The company reported in-line sales for the fourth quarter, but shares soared by double digits. 
Via Investor's Business Daily
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results. 
Via Benzinga
Advance Auto Parts Reports Q4 Results, Joins B&G Foods, Vipshop, ADT And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Dow Jones index falling around 100 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Earnings Scheduled For February 28, 2024
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.